NCT00603668View on ClinicalTrials.gov

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

January 31, 2013

Study Completion Date

February 28, 2013

Conditions
Chronic Lymphocytic Lymphoma
Interventions
BIOLOGICAL

milatuzumab

two or three times a week dosing of hLL1 for a total of 4 weeks

Trial Locations (5)

19104

University of Pennsylvania Cancer Center, Philadelphia

20007

Georgetown University Hospital Lombardi Cancer Center, Washington D.C.

32806

M. D. Anderson Cancer Center, Orlando

35294

Alabama at Birmingham Comprehensive Cancer Center, Birmingham

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00603668 - Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL | Biotech Hunter | Biotech Hunter